NO20081310L - Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme - Google Patents

Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme

Info

Publication number
NO20081310L
NO20081310L NO20081310A NO20081310A NO20081310L NO 20081310 L NO20081310 L NO 20081310L NO 20081310 A NO20081310 A NO 20081310A NO 20081310 A NO20081310 A NO 20081310A NO 20081310 L NO20081310 L NO 20081310L
Authority
NO
Norway
Prior art keywords
valsartan
amlodipine
dosage forms
solid dosage
preparing
Prior art date
Application number
NO20081310A
Other languages
English (en)
Norwegian (no)
Inventor
Robert Frank Wagner
Yatindra Joshi
Madhusudhan Pudipeddi
Gangadhar Sunkara
Li Ping
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37758280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081310(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081310L publication Critical patent/NO20081310L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20081310A 2005-08-17 2008-03-12 Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme NO20081310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70908305P 2005-08-17 2005-08-17
PCT/US2006/031699 WO2007022113A2 (en) 2005-08-17 2006-08-15 Solid dosage forms of valsartan and amlodipine and method of making the same

Publications (1)

Publication Number Publication Date
NO20081310L true NO20081310L (no) 2008-05-16

Family

ID=37758280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081310A NO20081310L (no) 2005-08-17 2008-03-12 Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme

Country Status (22)

Country Link
US (3) US20080171086A1 (ko)
EP (1) EP1917002A2 (ko)
JP (2) JP2009504744A (ko)
KR (3) KR20080034159A (ko)
CN (1) CN101237859A (ko)
AR (1) AR055120A1 (ko)
AU (2) AU2006279670A1 (ko)
BR (1) BRPI0614790A2 (ko)
CA (1) CA2617367A1 (ko)
EC (1) ECSP088188A (ko)
GT (1) GT200600371A (ko)
IL (1) IL189021A0 (ko)
MA (1) MA29734B1 (ko)
MX (1) MX2008002267A (ko)
NO (1) NO20081310L (ko)
NZ (1) NZ565020A (ko)
PE (1) PE20070420A1 (ko)
RU (2) RU2008109913A (ko)
TN (1) TNSN08071A1 (ko)
TW (1) TW200740432A (ko)
WO (1) WO2007022113A2 (ko)
ZA (1) ZA200800397B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
TR200703568A1 (tr) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
EP3067043B1 (en) 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
EP2240163A1 (en) * 2007-12-31 2010-10-20 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
EP2291233B1 (en) 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
EP2405899A2 (en) * 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
CN101926798B (zh) * 2009-06-26 2013-09-18 北京德众万全药物技术开发有限公司 一种含有氨氯地平和缬沙坦的分散片
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
CN101647797B (zh) * 2009-09-18 2011-06-08 海南锦瑞制药股份有限公司 一种含有苯磺酸氨氯地平和缬沙坦的药物组合物及其制备方法
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101843615A (zh) * 2010-06-25 2010-09-29 包丽昕 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法
TR201102067A1 (tr) 2011-03-03 2012-09-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Valsartan ve amlodipin kombinasyonları.
CN102283837A (zh) * 2011-07-29 2011-12-21 江苏省药物研究所有限公司 缬沙坦和氨氯地平复方的固体制剂的制备方法
CN102697778B (zh) * 2012-06-21 2014-04-30 上海医药集团股份有限公司 缬沙坦氨氯地平复方固体制剂及其制备方法
WO2013191668A1 (en) 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus
KR101778050B1 (ko) * 2012-10-12 2017-09-13 이에이 파마 가부시키가이샤 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
CN103006649B (zh) * 2012-12-27 2014-06-25 石家庄市华新药业有限责任公司 一种复方制剂缬沙坦氨氯地平片（ⅰ）及其制备方法
CZ2013783A3 (cs) * 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
ES2882672T3 (es) * 2015-07-08 2021-12-02 Hk Inno N Corp Composición farmacéutica que contiene amlodipino, valsartán, y rosuvastatina
CN105232551A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法
CN106176744A (zh) * 2016-07-13 2016-12-07 精华制药集团股份有限公司 缬沙坦氨氯地平胶囊在制备治疗脑中风的药物中的应用
US10695329B2 (en) 2016-10-07 2020-06-30 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
WO2018069823A1 (en) * 2016-10-10 2018-04-19 Alembic Pharmaceuticals Limited Stable pharmaceutical composition comprising telmisartan and amlodipine besylate
CN109498626A (zh) * 2017-09-14 2019-03-22 北京万全德众医药生物技术有限公司 一种稳定的复方制剂缬沙坦氨氯地平处方及其制备方法
WO2019200143A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN109260160A (zh) * 2018-08-30 2019-01-25 天津仁生医药科技有限公司 一种缬沙坦氨氯地平片剂及其制备方法
CN109157526A (zh) * 2018-09-13 2019-01-08 合肥合源药业有限公司 一种缬沙坦氨氯地平复方制剂及其制备工艺
CN109010338B (zh) * 2018-09-13 2021-09-21 合肥合源药业有限公司 一种缬沙坦氨氯地平片的制备方法及缬沙坦氨氯地平片
CN109394712B (zh) * 2018-11-23 2019-11-12 海南妙音春制药有限公司 一种缬沙坦氨氯地平复方片剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3152978B2 (ja) * 1991-12-17 2001-04-03 塩野義製薬株式会社 二層錠およびその製造方法
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DK2322174T3 (en) 1998-07-10 2015-10-12 Novartis Pharma Ag The combined use of valsartan and calcium channel blockers for therapeutic purposes
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE69935249T2 (de) 1998-12-23 2007-10-31 Novartis Ag Verwendung von at-1 rezeptorantagonisten oder at-2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
PT1467712E (pt) * 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
WO2006078574A2 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Mitotic kinesin inhibitors
TWI388345B (zh) * 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型

Also Published As

Publication number Publication date
ECSP088188A (es) 2008-03-26
US20100303906A1 (en) 2010-12-02
KR20080034159A (ko) 2008-04-18
CA2617367A1 (en) 2007-02-22
MA29734B1 (fr) 2008-09-01
RU2008109913A (ru) 2009-09-27
AR055120A1 (es) 2007-08-08
AU2006279670A1 (en) 2007-02-22
US20120177733A1 (en) 2012-07-12
AU2010227062A1 (en) 2010-11-04
RU2012131668A (ru) 2014-01-27
KR20120078751A (ko) 2012-07-10
PE20070420A1 (es) 2007-05-21
GT200600371A (es) 2007-03-21
ZA200800397B (en) 2009-03-25
CN101237859A (zh) 2008-08-06
JP2009504744A (ja) 2009-02-05
KR20120135356A (ko) 2012-12-12
WO2007022113A2 (en) 2007-02-22
TNSN08071A1 (en) 2009-07-14
US20080171086A1 (en) 2008-07-17
BRPI0614790A2 (pt) 2011-04-12
MX2008002267A (es) 2008-03-27
IL189021A0 (en) 2008-08-07
WO2007022113A3 (en) 2007-05-10
NZ565020A (en) 2011-07-29
JP2013091660A (ja) 2013-05-16
EP1917002A2 (en) 2008-05-07
TW200740432A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
NO20081310L (no) Faste doseringsformer for valsartan og amlodipin, og fremgangsmater for fremstilling av samme
HK1133818A1 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
NO20053245D0 (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
WO2009042114A3 (en) Phenazine derivatives and uses thereof
NO2012017I1 (no) Benzimidazolderivat, fremgangsmåte for fremstilling derav, medikament inneholdende denne forbindelsen samt anvendelse av forbindelsen.
BRPI0815773A2 (pt) composto, e, medicamento.
NO20080893L (no) Et CA6-anigenspesifikt, cytotoksisk konjugat og fremgangsmåter for anvendelse av det samme
NO20080784L (no) Histondeacetylaseinhibitorer
IS2577B (is) Trópan afleiður sem CCR5 stillar
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
NO20052158L (no) Fremgangsmate for fremstilling av en benzimidazolforbindelse.
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
IL182834A0 (en) Sulfonamido-macrocycles and the salts thereof, a pharmaceutical composition comprisng these compounds, the method of preparing and the use thereof
ITTO20060659A1 (it) Arresto di fondo corsa per una cerniera lampo, e cerniera lampo comprendente un tale arresto di fondo corsa.
WO2006052880A3 (en) Synergistic effects of combined administration of mirtazapine and a stimulant compound
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
TW200719901A (en) Therapeutic substituted cyclopentanones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application